Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease

European Journal of Surgical Oncology

Volumn 32, Issue 7, 2006, Pages 756-763

  Waas, E T ^a   Wobbes, Th ^a   Ruers, T ^a   Lomme, R M L M ^a   Hendriks, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood; Colorectal cancer; Liver; Marker; Matrix metalloproteinase

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ZYMOGRAPHY;

ADULT; AGED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 33747762613     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.03.028     Document Type: Article

References (28)

1. Fong Y., and Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol 26 5 (1999) 514-523
2. Hohenberger P., Schlag P.M., Gerneth T., and Herfarth C. Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases. Predictive value and implications for adjuvant treatment based on multivariate analysis. Ann Surg 219 2 (1994) 135-143
3. Brand K., Baker A.H., Perez-Canto A., Possling A., Sacharjat M., Geheeb M., et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 60 20 (2000) 5723-5730
4. Nordlinger B., Vaillant J.C., Guiguet M., Balladur P., Paris F., Bachellier P., et al. Survival Benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 12 7 (1994) 1491-1496
5. Nordlinger B., Guiguet M., Vaillant J.C., Balladur P., Boudjema K., Bachellier P., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77 7 (1996) 1254-1262
6. Schiedeck T.H., Wellm C., Roblick U.J., Broll R., and Bruch H.P. Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzyme-linked immunosorbent assay. Dis Colon Rectum 46 6 (2003) 818-825
7. Vihinen P., and Kahari V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99 2 (2002) 157-166
8. Stetler-Stevenson W.G., and Yu A.E. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 11 2 (2001) 143-152
9. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 3 (2002) 161-174
10. Zucker S., and Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23 1-2 (2004) 101-117
11. Waas E.T., Lomme R.-M.L.M., DeGroot J., Wobbes T., and Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 86 12 (2002) 1876-1883
12. Waas E.T., Wobbes T., Lomme R.M., DeGroot J., Ruers T., and Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 90 12 (2003) 1556-1564
13. Parsons S.L., Watson S.A., Collins H.M., Griffin N.R., Clarke P.A., and Steele R.J. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 78 11 (1998) 1495-1502
14. Watine J., Miedouge M., and Friedberg B. Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: a systematic review. Dis Colon Rectum 44 12 (2001) 1791-1799
15. Waas E.T., Hendriks T., Lomme R.-M.L.M., and Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 48 4 (2005) 700-710
16. Kleiner D.E., and Stetler Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218 2 (1994) 325-329
17. de Hingh I.H., Waas E.T., Lomme R.M., Wobbes T., and Hendriks T. Circulating matrix metalloproteinase-9 is transiently elevated after colorectal surgery. Int J Colorectal Dis 19 5 (2004) 446-450
18. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 3 (1988) 837-845
19. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 5564 (2002) 2387-2392
20. Mook O.R., Frederiks W.M., and Van Noorden C.J. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705 2 (2004) 69-89
21. Leeman M.F., Curran S., and Murray G.I. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201 4 (2003) 528-534
22. Iizasa T., Fujisawa T., Suzuki M., Motohashi S., Yasufuku K., Yasukawa T., et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 5 1 (1999) 149-153
23. Hrabec E., Strek M., Nowak D., and Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 95 1 (2001) 1-4
24. Ranuncolo S.M., Matos E., Loria D., Vilensky M., Rojo R., Bal-de-Kier-Joffe E., et al. Circulating 92-kilodalton matrix metalloproteinase (mmp-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer 94 5 (2002) 1483-1491
25. Lin S.Y., Wang Y.Y., and Sheu W.H. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Clin Endocrinol (Oxf) 58 4 (2003) 513-518
26. Sonnante A.M., Correale M., Linsalata M., Di Leo A., and Guerra V. Circulating levels of matrix metalloproteinase-9 in patients with colorectal cancer. Scand J Gastroenterol 35 6 (2000) 671-672
27. Holten-Andersen M.N., Stephens R.W., Nielsen H.J., Murphy G., Christensen I.J., Stetler-Stevenson W., et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6 11 (2000) 4292-4299
28. Holten Andersen M.N., Murphy G., Nielsen H.J., Pedersen A.N., Christensen I.J., Hoyer Hansen G., et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 80 3-4 (1999) 495-503